(11-L-THREONINE, 29-L-ARGININE)LACTOFERRIN(HUMAN) PRODUCED BY ASPERGILLUS NIGER VAR. AWAMORI
Tongue Cancer
Stanford Universityprotein_peptidePhase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Tongue Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cetuximab Fox Chase Cancer Center | Phase 1 | CCC |
(18F)FPPRGD2 Sanjiv Sam Gambhir | Phase 1/2 | CCC |
ANTI-HER2 ANTIBODY-DRUG CONJUGATE A166 Klus Pharma Inc. | Phase 1/2 | CCC |
FLUDEOXYGLUCOSE Sanjiv Sam Gambhir | Phase 1/2 | CCC |
Everolimus Fox Chase Cancer Center | Phase 1 | CC |
qbs10072s Quadriga Biosciences, Inc. | Phase 1 | CC |
Gefetinib National Cancer Institute (NCI) | N/A | D |
Same molecule, other indications
(11-L-THREONINE, 29-L-ARGININE)LACTOFERRIN(HUMAN) PRODUCED BY ASPERGILLUS NIGER VAR. AWAMORI is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →